A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Russian Federation flag in this illustration taken, October 30, 2020. The ratio of the placebo group to the vaccinated group is 1 to 3.
"The data demonstrating [the] high efficacy of the Sputnik V vaccine give us hope that we will soon obtain the most important tool in the fight against the pandemic of the novel coronavirus infection", noted Russian Health Minister Mikhail Murashko.
It will be free of charge for Russian citizens and will cost less than $10 per dose for worldwide recipients, said the RDIF, the sovereign wealth fund bankrolling and marketing the two-dose adenoviral vaccine.
Pharma giants Pfizer and BioNTech announced that their virus vaccine is 95 percent effective, while USA company Moderna said last week early results showed its candidate was 94.5 percent effective.
The Russian vaccine has proven to be unique since it uses two different vectors based on the human adenovirus, which allows for a stronger and longer-term immune response as compared with vaccines based on one and the same vector for both doses.
The interim research data will be published by the Gamaleya Center team in one of the leading worldwide peer-reviewed medical journals. Following the completion of phase-III clinical trials of the Sputnik V vaccine, Gamaleya Center will provide access to the full clinical trial report.
There were no unexpected adverse events during the trials.
The statement reported that the effectiveness of Sputnik-V exceeded 95 percent after 42 days of testing.
About two weeks ago, Sputnik V's developers claimed that the initial trial results have found the vaccine to be 92 per cent effective.
"Let me stress that the second analysis was conducted a week after volunteers got the second dose, meaning that their bodies have partially reacted to both doses. We are in constant touch with regulatory authorities from over 50 countries on the data and results of our clinical trials preliminary and interim data has already been given to WHO and in a number of other global organizations", Dmitriev said. Mr Dmitriev added Moscow aims to produce more than 1 billion doses at home and overseas next year. The vaccine supplies for the global market will be produced by RDIF's worldwide partners in India, Brazil, China, South Korea and other countries.